6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trialJoo‐Yong Hahn, Taek Kyu Park, Jeong Hoon Yang et al.|The Lancet|2018Cited by 372
Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trialKi Hong Choi, Joo-Yong Hahn, Yong Hwan Park et al.|The Lancet|2025Cited by 86
P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trialJi Woong Roh, Young Bin Song, Joo‐Yong Hahn et al.|Cardiology Journal|2021Cited by 23
Impact of Atrial Fibrillation on Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI): The K-TAVI RegistrySang Yoon Lee, Seung‐Hyuk Choi, Ki Hong Choi et al.|Yonsei Medical Journal|2023Cited by 12
Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Non-ST-Elevation Myocardial InfarctionChang‐Hoon Kim, Seung Hun Lee, Hyun Kuk Kim et al.|Circulation Journal|2024Cited by 6